Overview
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
- Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer.
- Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
- Participants must be able to comprehend English or Spanish (for survey completion).
- Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
- Completion of the confidential Self-Reported Screening Survey and receipt of a screening result – eligible for enrollment.
- Optional Sub-study (available at select sites only):
- Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
- Must be receiving treatment at the WF CCC and VCU.
- Must be diagnosed with non-small cell lung cancer.
- Must be receiving paclitaxel as part of their chemotherapy in conjunction with Immune Checkpoint Inhibitor (ICIs) PD-1, PD-L1 or CTLA-4.
- Must be enrolled and complete baseline survey before cycle 1 begins
- Patient Exclusion Criteria:
- Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
- Participants with known pregnancy.
- Optional Substudy (available at select sites only):
- Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed.
- Participants with a history of HIV, hepatitis B or hepatitis C.
Sponsor(s)
Wake Forest University Health Sciences
Learn More
To learn more, visit ClinicalTrials.Gov
Leave a Reply
You must be logged in to post a comment.